Shai Y. Yarkoni, Israel

cellect cellect
With formal and hands-on experience in Medicine, Science, Early-stage drug development, fund raising and international Start-up Management, my vision is to harness the multidisciplinary upbringing and accumulated experiences for building the Biotech industry in Israel 20 years of executive positions in the Biotechnology industry, 12 years of clinical experience and 10 years of research experience. Founder of 5 companies among them : Cellect Biotechnology (NASDAQ : APOP), BioNegev- the Innovation cluster of the Negev and Sne (rosetta IP) – National Tech transfer company. Founder and CEP of Cellect Biotechnology Ltd – clinical stage public company developing Cell based products for immune optimization.

Presenter of 1 Presentation

 Conference Calendar

EX-VIVO INCUBATION WITH FAS LIGAND SELECTIVELY DEPLETES ALLOREACTIVE T CELLS AND ANTIGEN PRESENTING CELLS – FROM HEMATOLOGICAL MALIGNANCIES TO AUTOIMMUNITY

Session Name
PS56 -T CELLS, T REGULATORY AND AUTOIMMUNITY
Session Type
PARALLEL SESSIONS
Date
01.06.2021, Tuesday
Session Time
08:00 - 10:00
Room
HALL C
Lecture Time
08:20 - 08:30
Presenter
Session Icon
Pre Recorded

Abstract

Background and Aims

Graft Vs Host disease (GvHD) remains the Achilles’ heel of hematopoietic stem cell transplantation: GvHD elicit patient 's risk for transplant-related mortality and decreased quality of life while treduced GvHD increase the risk of relapse.While GvHD is T cell mediated, the APCs are required for the initiation and maintenance of the GvHD. To reduce the risk for GvHD, grafts are sometimes depleted of their T cells, however, while preventing GvHD, the critically important attributes of rate and pace of engraftment and the graft versus leukemia (GvL) effect are reduced significantly. Novel strategies that aim to abrogate or ameliorate GvHD, while preserving engraftment and GvL are of great need.

Methods

A short incubation (2hr) of G-CSF mobilized PBCs with multimeric Fas ligand (i.e. ApoGraft) selectively induces apoptosis in T cell subsets and to a lesser degree in B cells and APCs, but not in CD34+ progenitor cells. FasL treatment preferentially induces apoptosis in mature T cell subsets which express high levels of Fas (CD95) as well as the pro-inflammatory T cell subtypes TH1 and TH17 cells, while no apoptotic signal is detected in Tregs and hematopoietic progenitor cells.

Results

In preliminary studies we tested the In-Vivo effect of FasL treated BMT in the context of diabetes type I and Osteoarthritis as two autoimmune models.

Conclusions

After initiating human trials in USA and Israel, Cellect is looking for the next indications where FasL Ex-Vivo treatment of Apheresis products can be adopted. Data and opportunities for this breakthrough technology will be presented.

Hide